ArticleJournal of global health2025
Application of GOLD 2023 Initial Inhalation Therapy Recommendations in COPD patients: a real-world adherence and prognosis analysis.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07543601 (Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined chronic obstructive pulmonary disease (COPD) assessment. Patients were classified into groups A, B, and E, and the initial inhalation therapy recommendations were revised. This study aimed to investigate the application status of initial inhalation therapy recommendations in patients with COPD and determine whether adherence to the GOLD 2023 report could achieve a better prognosis. Methods: This was a prospective cohort study. Demographic data, COPD assessment test (CAT) and modified Medical Research Council (mMRC) scores, pulmonary function, GOLD grades, GOLD groups, number of exacerbations, comorbidities, and inhalation therapy were collected. The patients were classified into adherent and non-adherent groups based on the provision of initial inhalation therapy recommendations that aligned with the GOLD A, B, and E groupings. All patients finished one year of follow-up to collect data on the number of exacerbations and mortality. Results: A total of 1654 patients were enrolled, of whom 816 (49.3%) were in the adherent group. The patients in the adherent group had higher age, CAT and mMRC scores, and number of exacerbations and hospitalisations, higher proportion of combined with lung cancer and chronic heart disease, and worse pulmonary function. Patients in the adherent group had lower future exacerbations, frequent exacerbations, and hospitalisations. The patients in groups B and E who adhered to the GOLD 2023 report had lower future exacerbations, frequent exacerbations, and hospitalisations, while no significant difference was observed in group A (P < 0.05). Conclusions: In the real world, many patients with COPD do not receive the initial inhalation therapy recommended by the GOLD 2023 report. However, adherence to the GOLD 2023 report may decrease the risk of future exacerbation. It implied that improved the dissemination and uptake of GOLD 2023 recommendations is needed in the clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.